- Tablets,
- Capsules,
- Powders & Granules (MT)
Oral Solid Dosage Contract Manufacturing Market size is valued at USD 22,678.1 million in 2022 and expected to grow at a significant CAGR of 6.4% during the forecast period 2023 to 2029. The global market provides a detailed overview and that can be segmented by product type, by release mechanism, and end user. By product type, the market has been segmented into Tablets, Capsules, Powders & Granules (MT). The Tablets segment is likely to be the largest and fastest-growing segment in terms of product type. Based By release mechanism, the market is segmented into Tablets (Immediate Release, Modified Release, Chewable Tablets, and Effervescent Tablets. Capsules (Controlled Release, Enteric Release, and Others), Powders & Granules (Uncoated Powders & Granules, Coated Granules). The tablets segment is expected to dominate the oral solid dosage contract manufacturing market. Based on the end user, the market has been segregated into Big Pharma or Biotech, Small & Medium Size Pharma or Biotech, Emerging or Virtual Pharma, and Nutraceutical Companies. The Big Pharma or Biotech segment is expected to dominate other segments in the Oral Solid Dosage Contract Manufacturing market according to Precision Business Insights.
Oral Solid Dosage Contract Manufacturing Market Key Developments:
In September 2018, Aurobindo acquired the dermatology and oral solids businesses from Sandoz Inc. This will support Sandoz’s strategy of focusing on complex generics, value-added medicines, and biosimilars to achieve sustainable and profitable growth in the U.S. over the long term.
Oral Solid Dosage Contract Manufacturing Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
5.8%
Largest Market
Asia Pacific
Fastest Growing Market
North America
Oral Solid Dosage Contract Manufacturing Market Drivers
Increase in the prevalence of chronic diseases such as diabetes, cardiovascular, cancers, and others is a key factor surge the growth of oral solid dosage form sales. Moreover, CMOs are offering cost-effective services, rise in R&D by the leading pharmaceutical companies, and long-term strategic alliances among the market players are immense boost to the market in the future.
North-America got significant share
Oral Solid Dosage Contract Manufacturing Market Regional Analysis
By region, the North America market is expected to witness highest market share during the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The global oral solid dosage contract manufacturing market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
- The oral solid dosage contract manufacturing market report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
- The oral solid dosage contract manufacturing market report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The oral solid dosage contract manufacturing market report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The oral solid dosage contract manufacturing market report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Oral Solid Dosage Contract Manufacturing Market Segmentation
By Product Type
By Release Mechanism
- Tablets (Immediate Release, Modified Release, Chewable Tablets, Effervescent Tablets),
- Capsules (Controlled Release, Enteric Release, Others),
- Powders & Granules (Uncoated Powders & Granules, Coated Granules)
By End User
- Big Pharma or Biotech,
- Small & Medium Size Pharma or Biotech,
- Emerging or Virtual Pharma,
- Nutraceutical Companies
Frequently Asked Questions
The Oral Solid Dosage Contract Manufacturing Market is projected to expand at a CAGR of 6.4% during the forecast period.
The major players in the global oral solid dosage contract manufacturing market are ??Abbvie Inc., Alcami Corporation, Cambrex Corporation (Halo Pharma), CMIC HOLDINGS Co., LTD., Confab Laboratories Inc. CordenPharma International, GENVION Corporation, Lonza Group AG, Mayne Pharma (Metrics Contract Services), Pfizer Inc., Pharma Tech Industries, Piramal Enterprises Ltd.
North America is the fastest-growing region for Oral Solid Dosage Contract Manufacturing Market
| 1. Executive Summary |
| 2. Global Oral Solid Dosage Contract Manufacturing Market Introduction |
| 2.1. Global Oral Solid Dosage Contract Manufacturing Market Taxonomy |
| 2.2. Global Oral Solid Dosage Contract Manufacturing Market Definitions |
| 2.2.1. Product |
| 2.2.2. Release Mechanism |
| 2.2.3. End User |
| 3. Global Oral Solid Dosage Contract Manufacturing Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Oral Solid Dosage Contract Manufacturing Market Dynamic Factors - Impact Analysis |
| 3.6. Global Oral Solid Dosage Contract Manufacturing Market Competition Landscape |
| 4. Global Oral Solid Dosage Contract Manufacturing Market Analysis,2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis,2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Oral Solid Dosage Contract Manufacturing Market, By Product, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Tablets |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Capsules |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Powders & Granules (MT) |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Oral Solid Dosage Contract Manufacturing Market Forecast, By Release Mechanism, 2018 - 2022 and Forecast, 2022 2028 (Revenue, USD Mn) |
| 6.1. Tablets |
| 6.1.1. Immediate Release |
| 6.1.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.1.3. Market Opportunity Analysis |
| 6.1.2. Modified Release |
| 6.1.2.1. Controlled Release |
| 6.1.2.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.2.1.3. Market Opportunity Analysis |
| 6.1.2.2. Enteric Release |
| 6.1.2.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.2.2.3. Market Opportunity Analysis |
| 6.1.2.3. Others |
| 6.1.2.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.2.3.3. Market Opportunity Analysis |
| 6.1.3. Chewable Tablets |
| 6.1.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3.3. Market Opportunity Analysis |
| 6.1.4. Effervescent Tablets |
| 6.1.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.4.3. Market Opportunity Analysis |
| 6.2. Capsules |
| 6.2.1. Controlled Release |
| 6.2.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.1.3. Market Opportunity Analysis |
| 6.2.2. Enteric Release |
| 6.2.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.2.3. Market Opportunity Analysis |
| 6.2.3. Others |
| 6.2.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3.3. Market Opportunity Analysis |
| 6.3. Powders & Granules (MT) |
| 6.3.1. Uncoated Powders & Granules |
| 6.3.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.1.3. Market Opportunity Analysis |
| 6.3.2. Coated Granules |
| 6.3.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.2.3. Market Opportunity Analysis |
| 7. Global Oral Solid Dosage Contract Manufacturing Market, By End User, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. Big Pharma or Biotech |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Small & Medium Size Pharma or Biotech |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Emerging or Virtual Pharma |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Nutraceutical Companies |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Oral Solid Dosage Contract Manufacturing Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User and Region, 2023 - 2029 |
| 9. North America Oral Solid Dosage Contract Manufacturing MarketAnalysis,2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Tablets |
| 9.1.2. Capsules |
| 9.1.3. Powders & Granules (MT) |
| 9.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Tablets |
| 9.2.1.1. Immediate Release |
| 9.2.1.2. Modified Release |
| 9.2.1.2.1. Controlled Release |
| 9.2.1.2.2. Enteric Release |
| 9.2.1.2.3. Others |
| 9.2.1.3. Chewable Tablets |
| 9.2.1.4. Effervescent Tablets |
| 9.2.2. Capsules |
| 9.2.2.1. Controlled Release |
| 9.2.2.2. Enteric Release |
| 9.2.2.3. Others |
| 9.2.3. Powders & Granules (MT) |
| 9.2.3.1. Uncoated Powders & Granules |
| 9.2.3.2. Coated Granules |
| 9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Big Pharma or Biotech |
| 9.3.2. Small & Medium Size Pharma or Biotech |
| 9.3.3. Emerging or Virtual Pharma |
| 9.3.4. Nutraceutical Companies |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 9.6. North America Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 10. Europe Oral Solid Dosage Contract Manufacturing Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Tablets |
| 10.1.2. Capsules |
| 10.1.3. Powders & Granules (MT) |
| 10.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Tablets |
| 10.2.1.1. Immediate Release |
| 10.2.1.2. Modified Release |
| 10.2.1.2.1. Controlled Release |
| 10.2.1.2.2. Enteric Release |
| 10.2.1.2.3. Others |
| 10.2.1.3. Chewable Tablets |
| 10.2.1.4. Effervescent Tablets |
| 10.2.2. Capsules |
| 10.2.2.1. Controlled Release |
| 10.2.2.2. Enteric Release |
| 10.2.2.3. Others |
| 10.2.3. Powders & Granules (MT) |
| 10.2.3.1. Uncoated Powders & Granules |
| 10.2.3.2. Coated Granules |
| 10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Big Pharma or Biotech |
| 10.3.2. Small & Medium Size Pharma or Biotech |
| 10.3.3. Emerging or Virtual Pharma |
| 10.3.4. Nutraceutical Companies |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Poland |
| 10.4.8. Rest of Europe |
| 10.5. Europe Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 10.6. Europe Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 11. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Tablets |
| 11.1.2. Capsules |
| 11.1.3. Powders & Granules (MT) |
| 11.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Tablets |
| 11.2.1.1. Immediate Release |
| 11.2.1.2. Modified Release |
| 11.2.1.2.1. Controlled Release |
| 11.2.1.2.2. Enteric Release |
| 11.2.1.2.3. Others |
| 11.2.1.3. Chewable Tablets |
| 11.2.1.4. Effervescent Tablets |
| 11.2.2. Capsules |
| 11.2.2.1. Controlled Release |
| 11.2.2.2. Enteric Release |
| 11.2.2.3. Others |
| 11.2.3. Powders & Granules (MT) |
| 11.2.3.1. Uncoated Powders & Granules |
| 11.2.3.2. Coated Granules |
| 11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Big Pharma or Biotech |
| 11.3.2. Small & Medium Size Pharma or Biotech |
| 11.3.3. Emerging or Virtual Pharma |
| 11.3.4. Nutraceutical Companies |
| 11.4. Country Analysis2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 11.6. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 12. Latin America Oral Solid Dosage Contract Manufacturing Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Tablets |
| 12.1.2. Capsules |
| 12.1.3. Powders & Granules (MT) |
| 12.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Tablets |
| 12.2.1.1. Immediate Release |
| 12.2.1.2. Modified Release |
| 12.2.1.2.1. Controlled Release |
| 12.2.1.2.2. Enteric Release |
| 12.2.1.2.3. Others |
| 12.2.1.3. Chewable Tablets |
| 12.2.1.4. Effervescent Tablets |
| 12.2.2. Capsules |
| 12.2.2.1. Controlled Release |
| 12.2.2.2. Enteric Release |
| 12.2.2.3. Others |
| 12.2.3. Powders & Granules (MT) |
| 12.2.3.1. Uncoated Powders & Granules |
| 12.2.3.2. Coated Granules |
| 12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Big Pharma or Biotech |
| 12.3.2. Small & Medium Size Pharma or Biotech |
| 12.3.3. Emerging or Virtual Pharma |
| 12.3.4. Nutraceutical Companies |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 12.6. Latin America Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 13. Middle East and Africa Oral Solid Dosage Contract Manufacturing Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 13.1. By Product Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Tablets |
| 13.1.2. Capsules |
| 13.1.3. Powders & Granules (MT) |
| 13.2. Release Mechanism Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Tablets |
| 13.2.1.1. Immediate Release |
| 13.2.1.2. Modified Release |
| 13.2.1.2.1. Controlled Release |
| 13.2.1.2.2. Enteric Release |
| 13.2.1.2.3. Others |
| 13.2.1.3. Chewable Tablets |
| 13.2.1.4. Effervescent Tablets |
| 13.2.2. Capsules |
| 13.2.2.1. Controlled Release |
| 13.2.2.2. Enteric Release |
| 13.2.2.3. Others |
| 13.2.3. Powders & Granules (MT) |
| 13.2.3.1. Uncoated Powders & Granules |
| 13.2.3.2. Coated Granules |
| 13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Big Pharma or Biotech |
| 13.3.2. Small & Medium Size Pharma or Biotech |
| 13.3.3. Emerging or Virtual Pharma |
| 13.3.4. Nutraceutical Companies |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Oral Solid Dosage Contract Manufacturing Market - Opportunity Analysis Index, By Product, Release Mechanism, End User, and Country, 2023 - 2029 |
| 13.6. MEA Oral Solid Dosage Contract Manufacturing Market Dynamics Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2.1. ??Abbvie Inc. |
| 14.2.2. Alcami Corporation |
| 14.2.3. Cambrex Corporation (Halo Pharma) |
| 14.2.4. CMIC HOLDINGS Co., LTD. |
| 14.2.5. Confab Laboratories Inc. |
| 14.2.6. CordenPharma International |
| 14.2.7. GENVION Corporation |
| 14.2.8. Lonza Group AG |
| 14.2.9. Mayne Pharma (Metrics Contract Services) |
| 14.2.10. Pfizer Inc. |
| 14.2.11. Pharma Tech Industries |
| 14.2.12. Piramal Enterprises Ltd. |
| 14.2.13. PNP Pharmaceuticals Inc. |
| 14.2.14. ThermoFisher Scientific Inc. (Patheon N.V.) |
| 14.2.15. Tower Laboratories Ltd. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- Abbvie Inc.
- Alcami Corporation
- Cambrex Corporation (Halo Pharma)
- CMIC HOLDINGS Co., LTD.
- Confab Laboratories Inc.
- CordenPharma International
- GENVION Corporation
- Lonza Group AG
- Mayne Pharma (Metrics Contract Services)
- Pfizer Inc.
- Pharma Tech Industries
- Piramal Enterprises Ltd.
- PNP Pharmaceuticals Inc.
- ThermoFisher Scientific Inc. (Patheon N.V.)
- Tower Laboratories Ltd.